5-Lipoxygenase mediates RANKL-induced osteoclast formation via the cysteinyl leukotriene receptor 1

Journal of Immunology

Volumn 189, Issue 11, 2012, Pages 5284-5292

  Lee, Jung Min ^a   Park, Hyojung ^a,b   Noh, A Long Sae Mi ^a   Kang, Ju Hee ^a   Chen, Ling ^a   Zheng, Ting ^a   Lee, Juhyun ^a   Ji, Sun Young ^a   Jang, Chang Young ^a   Shin, Chan Soo ^b   Ha, Hyunil ^c,f   Lee, Zang Hee ^c   Park, Hea Young ^d   Lee, Dong Seok ^e   Yim, Mijung ^a  

^a Sookmyung Women's University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Ewha Womans University   (South Korea)

^e Kyungpook National University   (South Korea)

^f Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,6 DIHYDROXYHEXYL) 6 (3 HYDROXY 1,5 UNDECADIENYL)PYRIDINE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5 ETHYL 2 HYDROXY 4 [6 METHYL 6 (1H TETRAZOL 5 YL)HEPTYLOXY]ACETOPHENONE; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; ARACHIDONATE 5 LIPOXYGENASE; I KAPPA B; LEUKOTRIENE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONTELUKAST; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PEPTIDOLEUKOTRIENE; PEPTIDOLEUKOTRIENE RECEPTOR 1; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE MARROW DERIVED MACROPHAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BONE MARROW; BONE RESORPTION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; I-KAPPA B KINASE; INDOLES; LIPOPOLYSACCHARIDES; LIPOXYGENASE INHIBITORS; MACROPHAGES; MALE; MICE; MICE, INBRED ICR; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RANK LIGAND; RECEPTORS, LEUKOTRIENE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84869826356     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003738     Document Type: Article

References (36)

1. Takahashi, N., T. Akatsu, N. Udagawa, T. Sasaki, A. Yamaguchi, J. M. Moseley, T. J. Martin, and T. Suda. 1988. Osteoblastic cells are involved in osteoclast formation. Endocrinology 123: 2600-2602.
2. Suda, T., N. Takahashi, N. Udagawa, E. Jimi, M. T. Gillespie, and T. J. Martin. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20: 345-357. (Pubitemid 30649812)
3. Wong, B. R., J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov, E. Cayani, F. S. Bartlett, III, W. N. Frankel, et al. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun Nterminal kinase in T cells. J. Biol. Chem. 272: 25190-25194. (Pubitemid 27415705)
4. Yasuda, H., N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95: 3597-3602.
5. Walsh, M. C., and Y. Choi. 2003. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 14: 251-263. (Pubitemid 36693145)
6. Peters-Golden, M., and W. R. Henderson, Jr. 2007. Leukotrienes. N. Engl. J. Med. 357: 1841-1854.
7. Murphy, R. C., and M. A. Gijón. 2007. Biosynthesis and metabolism of leukotrienes. Biochem. J. 405: 379-395. (Pubitemid 47172035)
8. Rådmark, O., O. Werz, D. Steinhilber, and B. Samuelsson. 2007. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci. 32: 332-341. (Pubitemid 47021417)
9. Yokomizo, T., T. Izumi, K. Chang, Y. Takuwa, and T. Shimizu. 1997. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387: 620-624. (Pubitemid 27248768)
10. Yokomizo, T., K. Kato, K. Terawaki, T. Izumi, and T. Shimizu. 2000. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 192: 421-432.
11. Lynch, K. R., G. P. O'Neill, Q. Liu, D. S. Im, N. Sawyer, K. M. Metters, N. Coulombe, M. Abramovitz, D. J. Figueroa, Z. Zeng, et al. 1999. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399: 789-793. (Pubitemid 29293175)
12. Heise, C. E., B. F. O'Dowd, D. J. Figueroa, N. Sawyer, T. Nguyen, D. S. Im, R. Stocco, J. N. Bellefeuille, M. Abramovitz, R. Cheng. 2000. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275: 30531-30536.
13. Takasaki, J., M. Kamohara, M. Matsumoto, T. Saito, T. Sugimoto, T. Ohishi, H. Ishii, T. Ota, T. Nishikawa, Y. Kawai, et al. 2000. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem. Biophys. Res. Commun. 274: 316-322. (Pubitemid 30614317)
14. Bonewald, L. F., M. Flynn, M. Qiao, M. R. Dallas, G. R. Mundy, and B. F. Boyce. 1997. Mice lacking 5-lipoxygenase have increased cortical bone thickness. Adv. Exp. Med. Biol. 433: 299-302. (Pubitemid 28231835)
15. Garcia, C., B. F. Boyce, J. Gilles, M. Dallas, M. Qiao, G. R. Mundy, and L. F. Bonewald. 1996. Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. J. Bone Miner. Res. 11: 1619-1627. (Pubitemid 26367672)
16. Hikiji, H., S. Ishii, T. Yokomizo, T. Takato, and T. Shimizu. 2009. A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss. Proc. Natl. Acad. Sci. USA 106: 21294-21299.
17. Traianedes, K., M. R. Dallas, I. R. Garrett, G. R. Mundy, and L. F. Bonewald. 1998. 5-Lipoxygenase metabolites inhibit bone formation in vitro. Endocrinology 139: 3178-3184. (Pubitemid 28512347)
18. Ha, H., J. H. Lee, H. N. Kim, H. M. Kim, H. B. Kwak, S. Lee, H. H. Kim, and Z. H. Lee. 2006. alpha-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis. J. Immunol. 176: 111-117. (Pubitemid 43023254)
19. Takayanagi, H. 2007. The role of NFAT in osteoclast formation. Ann. N. Y. Acad. Sci. 1116: 227-237. (Pubitemid 350274348)
20. Kim, K., J. H. Kim, J. Lee, H. M. Jin, S. H. Lee, D. E. Fisher, H. Kook, K. K. Kim, Y. Choi, and N. Kim. 2005. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J. Biol. Chem. 280: 35209-35216. (Pubitemid 41532708)
21. Matsumoto, M., M. Kogawa, S. Wada, H. Takayanagi, M. Tsujimoto, S. Katayama, K. Hisatake, and Y. Nogi. 2004. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J. Biol. Chem. 279: 45969-45979. (Pubitemid 39491590)
22. Yagi, M., K. Ninomiya, N. Fujita, T. Suzuki, R. Iwasaki, K. Morita, N. Hosogane, K. Matsuo, Y. Toyama, T. Suda, and T. Miyamoto. 2007. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms. J. Bone Miner. Res. 22: 992-1001. (Pubitemid 351339721)
23. Lee, J., K. Kim, J. H. Kim, H. M. Jin, H. K. Choi, S. H. Lee, H. Kook, K. K. Kim, Y. Yokota, S. Y. Lee, et al. 2006. Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood 107: 2686-2693.
24. Kim, K., J. H. Kim, J. Lee, H. M. Jin, H. Kook, K. K. Kim, S. Y. Lee, and N. Kim. 2007. MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 109: 3253-3259. (Pubitemid 46572510)
25. Zhao, B., M. Takami, A. Yamada, X. Wang, T. Koga, X. Hu, T. Tamura, K. Ozato, Y. Choi, L. B. Ivashkiv, et al. 2009. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat. Med. 15: 1066-1071.
26. Miyauchi, Y., K. Ninomiya, H. Miyamoto, A. Sakamoto, R. Iwasaki, H. Hoshi, K. Miyamoto, W. Hao, S. Yoshida, H. Morioka, et al. 2010. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J. Exp. Med. 207: 751-762.
27. Mehta, M., P. Strube, A. Peters, C. Perka, D. Hutmacher, P. Fratzl, and G. N. Duda. 2010. Influences of age and mechanical stability on volume, microstructure, and mineralization of the fracture callus during bone healing: is osteoclast activity the key to age-related impaired healing? Bone 47: 219-228.
28. Cottrell, J. A., and J. P. O'Connor. 2009. Pharmacological inhibition of 5-lipoxygenase accelerates and enhances fracture-healing. J. Bone Joint Surg. Am. 91: 2653-2665.
29. Evans, J. F. 2002. Cysteinyl leukotriene receptors. Prostaglandins Other Lipid Mediat. 68-69: 587-597. (Pubitemid 35247422)
30. Chan, C. C., P. Ecclestone, D. W. Nicholson, K. M. Metters, D. J. Pon, and I. W. Rodger. 1994. Leukotriene D4-induced increases in cytosolic calcium in THP-1 cells: dependence on extracellular calcium and inhibition with selective leukotriene D4 receptor antagonists. J. Pharmacol. Exp. Ther. 269: 891-896.
31. Mellor, E. A., A. Maekawa, K. F. Austen, and J. A. Boyce. 2001. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc. Natl. Acad. Sci. USA 98: 7964-7969. (Pubitemid 32642670)
32. Capra, V., M. R. Accomazzo, S. Ravasi, M. Parenti, M. Macchia, S. Nicosia, and G. E. Rovati. 2003. Involvement of prenylated proteins in calcium signaling induced by LTD4 in differentiated U937 cells. Prostaglandins Other Lipid Mediat. 71: 235-251. (Pubitemid 36929793)
33. Negishi-Koga, T., and H. Takayanagi. 2009. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol. Rev. 231: 241-256.
34. Young, R. N. 1999. Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized? Eur. J. Med. Chem. 34: 671-685. (Pubitemid 29491553)
35. Berger, W., M. T. De Chandt, and C. B. Cairns. 2007. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int. J. Clin. Pract. 61: 663-676. (Pubitemid 46449830)
36. Diamant, Z., E. Mantzouranis, and L. Bjermer. 2009. Montelukast in the treatment of asthma and beyond. Expert Rev. Clin. Immunol. 5: 639-658.